Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis
Authors:
- 5 October 2024
- journal article
- research article
- Published by Springer Nature in CNS Drugs
- Vol. 38 (11) , 931-941
Abstract
Ozanimod (Zeposia®), an orally administered sphingosine 1-phosphate (S1P) receptor modulator (S1PRM) that is selective for the S1P1 and S1P5 receptor subtypes, is approved in the USA for relapsing forms of multiple sclerosis (RMS). In pivotal phase III clinical trials in patients with RMS, ozanimod significantly reduced annualised relapse rates and the number of new or enlarging T2 lesions and gadolinium-enhancing lesions, and was associated with reduced brain volume loss, compared with interferon (IFN)-β1a. However, there were no significant differences in 3- and 6-month disability progression between the groups. Ozanimod was generally well tolerated, with the most common adverse reactions including upper respiratory tract infection and hepatic transaminase elevation. Efficacy and tolerability were sustained over more than 6 years with continued treatment. S1PRM-related adverse events seen with ozanimod are generally manageable with screening and/or monitoring. Notably, ozanimod does not require first-dose cardiac monitoring in the USA. In conclusion, ozanimod is a valuable once-daily oral disease-modifying therapy that extends the available treatment options for patients with RMS.Keywords
This publication has 33 references indexed in Scilit:
- Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical reviewAnnals of Clinical and Translational Neurology, 2024
- SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosisAnnals of Clinical and Translational Neurology, 2023
- Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparisonMultiple Sclerosis and Related Disorders, 2023
- The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccinationMultiple Sclerosis and Related Disorders, 2022
- Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse RateMultiple Sclerosis and Related Disorders, 2022
- Ozanimod in relapsing forms of multiple sclerosis: a profile of its useDrugs & Therapy Perspectives, 2021
- Concentration‐QTc Modeling of Ozanimod’s Major Active Metabolites in Adult Healthy SubjectsCPT: Pharmacometrics & Systems Pharmacology, 2020
- Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy SubjectsAdvances in Therapy, 2020
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trialThe Lancet Neurology, 2019
- Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trialThe Lancet Neurology, 2016